CRISPR Gene Editing Therapy CTX310 Lowers LDL-C and Triglycerides in Lipid Disorders

CTX310, a one-time CRISPR-Cas9 gene-editing therapy, has safely reduced LDL cholesterol and triglycerides in adult patients with difficult-to-treat lipid disorders.¹

Presented at the American Heart Association’s Scientific Sessions 2025 in New…